(ALLO) Allogene Therapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ALLO) Allogene Therapeutics, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Allogene Therapeutics, Inc. BCG Matrix helps you quickly see how the company’s products or business units may fall into Stars, Cash Cows, Question Marks, and Dogs for strategy, research, and capital allocation. The content shown on this page is a real preview of the actual analysis, not just a sample layout. Buy the full version to get the complete ready-to-use BCG Matrix instantly.
Stars
cema-cel ALLO-501A
cema-cel ALLO-501A is Allogene Therapeutics, Inc.'s lead CD19 allogeneic CAR T for relapsed or refractory large B-cell lymphoma, and it sits in the Stars quadrant because it is the pipeline’s most advanced value driver. As of 2025, it is the clearest candidate for a future commercial launch and a shot at a large oncology market. Its lead status makes it the key swing asset for Allogene Therapeutics, Inc.'s near-term growth story.
ALLO-316 CD70 RCC
ALLO-316 CD70 RCC is a high-upside Star for Allogene Therapeutics, Inc. Renal cell carcinoma makes up about 90% of kidney cancers, and CAR T has very limited penetration in solid tumors. The program expands Allogene beyond blood cancers, and if it shows durable activity in RCC, the platform could re-rate fast.
ALLO-715 BCMA MM
ALLO-715 targets relapsed/refractory multiple myeloma, a market with about 35,000 new U.S. cases a year and strong demand for BCMA therapies. It gives Allogene Therapeutics, Inc. a shot at the large CAR T space, where approved BCMA drugs already show multibillion-dollar demand. Positive data would matter a lot because it could lift a late-stage asset in a crowded field.
ALLO-647 CD52 backbone
ALLO-647 is a CD52-directed lymphodepletion antibody that Allogene Therapeutics, Inc. uses across its trial regimen, so it acts more like a platform enabler than a product. It is not a commercial drug, which means its current revenue is 0, but its role in preparing patients for cell therapy makes it central to the pipeline.
In BCG terms, that makes ALLO-647 a Star-like backbone asset: high strategic importance, tied to multiple programs, and critical to execution. If Allogene converts its allogeneic CAR T trials into repeatable outcomes, ALLO-647 helps protect that value at the treatment-design level.
- 0 commercial sales today
- Core to trial conditioning
- Supports multiple programs
- Platform-level strategic asset
Allogene CAR T platform
Allogene Therapeutics, Inc.'s allogeneic CAR T platform is the main asset: it is built to manufacture off-the-shelf T cells at scale and supports multiple programs, not just one lead drug. If the platform keeps showing durable cell expansion and safety, it can turn single-program data into a wider franchise.
The market is still early, but the platform's value is in reuse: one engineering base can feed several candidates and partner deals. In 2025, Allogene Therapeutics, Inc. reported no product revenue and relied on its cash runway to fund development, so platform durability matters more than near-term sales.
- Core asset drives multiple programs
- Durability can widen the franchise
- Cash-backed, pre-revenue model
Allogene’s Star Assets Could Drive Its First Sales
Stars in Allogene Therapeutics, Inc. are led by cema-cel ALLO-501A, ALLO-316, and ALLO-715: the most advanced assets with the clearest shots at future sales. Allogene Therapeutics, Inc. reported 0 product revenue in 2025, so these programs matter because they can turn a pre-revenue platform into a commercial one.
| Asset | Role | 2025 |
|---|---|---|
| cema-cel ALLO-501A | Lead Star | Most advanced |
| ALLO-316 | Solid tumor Star | High-upside |
| ALLO-715 | Myeloma Star | Late-stage |
What is included in the product
Detailed Word Document
Allogene’s BCG Matrix is mostly Question Marks, with pipeline potential but no Cash Cows, demanding selective investment and tight capital control.
Editable Excel File
One-page BCG Matrix for Allogene Therapeutics, Inc. to quickly spot pain points and prioritize each business unit.
Reference Sources
Allogene Therapeutics, Inc. Reference Sources provide a credible audit trail that supports faster due diligence and more confident decision-making.
Cash Cows
Cash and marketable securities
At end-2025, Allogene Therapeutics, Inc. was still pre-revenue, so cash and marketable securities were its main operating cushion, not a product cash cow. The treasury funded R&D and clinical trials, while quarterly cash burn stayed the key metric to watch. That makes this a balance-sheet backed support pool, with no revenue engine yet.
Pfizer alliance
The Pfizer alliance can add non-dilutive cash through milestones and shared development costs, which matters for a small biotech with heavy clinical burn. In BCG terms, that makes it a Cash Cow-style support asset: low-growth, but still a cash contributor. The real value is funding runway without new share issuance, if partnership receipts keep coming.
Servier alliance
Servier has been one of Allogene Therapeutics, Inc.'s key partners, and that matters because alliance payments can help fund R&D without adding as much dilution. In a cash-cow sense, this keeps pipeline optionality alive while easing pressure on Allogene Therapeutics, Inc.'s cash burn. The relationship is practical, not flashy: shared economics can turn a high-cost cell therapy platform into a steadier cash-supporting asset.
Cellectis license rights
Allogene Therapeutics, Inc.'s Cellectis license rights stay a cash cow because they can bring milestone and development funding without the cost of a full commercial build. In a mature partner model, the value sits in recurring economics, not near-term sales. The 2025 filings still show this as a low-capex way to monetize core cell-therapy IP.
- Milestone-led cash, not heavy spend
- Partner economics from licensed IP
- Strategic value stays high in 2025
MD Anderson collaboration
Allogene Therapeutics, Inc.’s MD Anderson collaboration helps fund preclinical and clinical work, so it lowers discovery and validation spend while keeping pipeline testing moving. In 2025, Allogene reported $276.9 million in cash, cash equivalents, and investments as of December 31, 2025, giving this academic tie-up added runway value. For a BCG view, it acts like steady, low-growth support capital, not a fast sales driver.
- Reduces early R&D burden
- Supports pipeline validation
- Extends cash runway efficiency
Allogene’s Cash Cow Is Partner Economics, Not Product Sales
Allogene Therapeutics, Inc. has no product cash cow in 2025; its only cash-supporting assets are partner economics, milestone receipts, and its $276.9 million cash, cash equivalents, and investments at December 31, 2025. That support keeps R&D moving while reducing dilution pressure. In BCG terms, these alliances are the nearest thing to a Cash Cow.
| Item | 2025 data |
|---|---|
| Cash, cash equivalents, investments | $276.9 million |
| Revenue base | Pre-revenue |
| Cash-cow source | Partner milestones and shared costs |
Preview the Actual Deliverable
Allogene Therapeutics, Inc. Reference Sources
You're previewing the exact Allogene Therapeutics, Inc. BCG Matrix report you'll receive after purchase. The full document is the same file—no demo pages, no placeholders, and no watermarks. It’s ready for immediate use in strategy reviews, presentations, or research.
Once you buy, you’ll get the complete, professionally formatted version right away. What you see here is precisely what will be delivered to you.
Dogs
Legacy ALLO-501
Legacy ALLO-501 fits the Dogs bucket: it was overtaken by later lead programs and, by end-2025, had little standalone strategic value. Allogene Therapeutics, Inc. kept the asset in the background while newer candidates drew capital and attention, leaving ALLO-501 as a low-share, low-growth legacy program. With no clear separate commercial path and no reported 2025 revenue contribution, its portfolio weight stayed minimal.
ALLO-605 MM
ALLO-605 sits in a crowded multiple myeloma market where CAR-T rivals like Abecma and Carvykti already have stronger clinical and commercial traction, so the program had far less visibility than Allogene Therapeutics, Inc.'s lead assets. With no late-stage value driver or revenue yet tied to ALLO-605, it looks like a BCG "dog" unless new 2025-2026 data materially improve response and durability. In a field with high trial density and fast-moving standards of care, weak differentiation keeps the upside limited.
ALLO-819 AML
ALLO-819 for AML fits a Dog case: acute myeloid leukemia is scientifically attractive, but relapse, resistance, and patient mix make it hard to crack. By end-2025, the asset was still early and had no clear commercial path, while Allogene Therapeutics, Inc. kept it in a high-risk, low-momentum stage. That mix points to weak near-term value creation.
DLL3 SCLC
DLL3 in small cell lung cancer is still an early, capital-heavy bet, and Allogene Therapeutics, Inc. has no proven commercial edge in this space. With no approved Allogene DLL3 product and weak differentiation versus rivals, the asset fits the Dog quadrant more than a growth story.
- Early stage, high burn
- No proven market position
- Weak differentiation risk
- Dog quadrant fit
Deprioritized early cohorts
Allogene Therapeutics, Inc. has deprioritized older cohorts like early ALLO-501/501A and other redundant studies as cema-cel and newer programs took the lead. That fits a BCG "dog": they still use trial slots and team time, but they add little near-term value or clear 2025/2026 upside. In a cash-constrained biotech, that capital and attention should stay on the few shots with real readout potential.
- Old cohorts now look non-core
- Lead assets drive most value
- Low growth, low strategic payoff
Allogene’s Legacy Programs Still Burn Cash, With Little 2025/26 Upside
Allogene Therapeutics, Inc.'s Dogs are legacy or weakly differentiated programs that still consume cash but add little 2025/2026 value. ALLO-501, ALLO-605, ALLO-819, and DLL3 all fit low-share, low-growth profiles, with no reported revenue contribution and limited near-term commercial pull.
| Program | Dog signal | 2025/2026 cue |
|---|---|---|
| ALLO-501 | Legacy | No standalone value |
| ALLO-605 | Low share | Crowded market |
| ALLO-819 | Early risk | No clear path |
| DLL3 | Unproven | No approved product |
Question Marks
cema-cel launch path
As of end-2025, cema-cel had no approved sales, so Allogene Therapeutics, Inc. still treated it as a Question Mark in the BCG Matrix. Its value depends on clinical conversion, FDA execution, and market uptake, not revenue yet; until approval, it stays a high-growth, high-risk bet.
ALLO-316 expansion
ALLO-316’s RCC expansion still fits a question mark: it targets a market with real upside, but Allogene Therapeutics, Inc. has not yet shown commercial proof. Solid tumor CAR T is still a hard category, with uptake limited by safety, trafficking, and durability issues. Until more clinical data confirm response and consistency, this program should stay in question mark status.
ALLO-715 durability
Multiple myeloma remains a large, growing market, but ALLO-715 still needs durable clinical proof to matter commercially. It has shown early activity, yet it has not won any market share, so its share is still 0%. That is classic question mark territory: upside is real, but long-term validation is still missing.
UCART19 pediatric and adult ALL
UCART19 in pediatric and adult ALL is a true question mark: CD19 relapsed or refractory ALL is a high-need setting, but UCART19 remained a development-stage asset through end-2025 and was not a market leader. The opportunity is real, yet the path to share is still unproven.
In B-ALL, published CD19 CAR-T data have shown complete remission rates above 70% in heavily pretreated patients, so the market is attractive if Allogene Therapeutics, Inc. can convert efficacy into durable use. Still, with no approved UCART19 product by end-2025, it stays high-potential but not yet a star.
- High need: relapsed/refractory ALL
- Stage risk: still development-stage
- Share risk: not a leader by end-2025
- Upside tied to durable remission data
Next-gen allogeneic T-cell candidates
Allogene Therapeutics, Inc.’s next-gen allogeneic T-cell candidates are still Question Marks: high-growth assets with low market share until data de-risks them. The company’s future depends on moving more engineered T-cell programs forward, but each step raises R&D spend and cash burn before revenue follows.
Pipeline upside is real, but unproven.
Clinical wins can create future Stars.
Failure would keep share and returns low.
Allogene’s Pipeline Stays a High-Risk Question Mark
As of end-2025, Allogene Therapeutics, Inc. still had no approved sales from cema-cel, so it stayed a Question Mark. ALLO-316, ALLO-715, UCART19, and next-gen T-cell assets also remained low-share, high-upside bets, with value still tied to data readouts, FDA steps, and durable responses.
| Asset | End-2025 status | BCG view |
|---|---|---|
| cema-cel | No approved sales | Question Mark |
| ALLO-316 | RCC expansion still unproven | Question Mark |
| ALLO-715 | Early activity, 0% share | Question Mark |
| UCART19 | Development-stage, no lead share | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.